IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

Rhea-AI Summary

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on Thursday, December 15, 2022, at 10:30 am Eastern Time to discuss its quarterly results and recent business highlights for Q2 fiscal year 2023. The company plans to release its financial results prior to the call. The management will take questions from participants following the presentation. Interested parties can join the call via provided phone numbers and a live webcast, which will also be available for replay on the company's investor relations page.

Positive

• Planned earnings call indicates transparency and communication with investors.

Negative

• None.

The Company to host an earnings conference call via webcast

VICTORIA, British Columbia--(BUSINESS WIRE)-- IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.

ImmunoPrecise management will host the conference call followed by a question-and-answer period.

Conference Call:

Date: Thursday, December 15, 2022
Time: 10:30 am Eastern time

Participant Info:

Conference ID: 9236374
Participant Toll-Free Dial-In Number: 1 (888) 550-5658
Participant Toll Dial-In Number: 1 (646) 960-0289

Attendee URL: https://events.q4inc.com/attendee/662019205

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005242/en/

Investor contact: investors@immunoprecise.com

Source: ImmunoPrecise Antibodies Ltd.

FAQ

When is ImmunoPrecise Antibodies' next earnings call?

ImmunoPrecise Antibodies' next earnings call is scheduled for December 15, 2022, at 10:30 am Eastern Time.

What will be discussed in the earnings call for IPA?

The earnings call will cover quarterly results and recent business highlights for Q2 fiscal year 2023.

Where can I find the financial results prior to the earnings call for IPA?

The financial results will be issued in a press release before the earnings call.

How can I access the earnings call for ImmunoPrecise Antibodies?

You can access the earnings call by dialing the provided toll-free or toll numbers, or by joining the live webcast through the company's investor relations page.